RefleXion Medical, Inc.

RefleXion Medical develops biology-guided radiotherapy (BGRT) systems for cancer treatment. The company's flagship product, the RefleXion X1 machine with SCINTIX autonomous radiotherapy, combines PET (positron-emission tomography) imaging with linear accelerator (LINAC) radiation therapy to enable real-time tumor tracking and treatment delivery. SCINTIX detects biological signals emitted by cancer cells after radiopharmaceutical injection and uses this information to autonomously guide radiation beams to tumors in motion, potentially reducing dose to surrounding healthy tissue. The system is FDA-cleared for treatment of lung and bone tumors, including primary and metastatic disease at any stage. In addition to SCINTIX therapy, the RefleXion X1 platform delivers conventional radiotherapy modalities including SBRT (stereotactic body radiation therapy), SRS (stereotactic radiosurgery), and IMRT (intensity-modulated radiation therapy) for solid tumors throughout the body. The platform is designed to fit standard radiotherapy vaults with minimal shielding modifications and is compatible with third-party immobilization devices and existing contouring tools. Founded in 2009 by Sam Mazin, Ph.D. and Akshay Nanduri, RefleXion has secured over $400 million in venture financing and employs more than 250 people. Leadership includes Todd Powell (President and CEO, formerly of Elekta) and Martyn Webster (CFO). SCINTIX therapy has achieved Medicare reimbursement through multiple Medicare Administrative Contractors (MACs), supporting adoption in freestanding cancer centers and hospital outpatient departments. The company targets oncology departments, cancer centers, and radiation therapy facilities.